Nielsen, Mette Søndergaard https://orcid.org/0000-0001-7354-4648
Brøndsted, Lise
Kankam, Martin https://orcid.org/0000-0002-4168-4838
Morelli, Gaetano https://orcid.org/0009-0005-8238-8751
Nguyen, David https://orcid.org/0009-0005-8562-1977
Skjøth, Trine Vang https://orcid.org/0009-0001-4101-4703
Patted, Usha Rani https://orcid.org/0000-0002-4815-3300
van Hout, Marloes https://orcid.org/0000-0002-5753-9563
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
https://doi.org/10.1007/s13300-024-01674-8
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 6 September 2024
Accepted: 20 November 2024
First Online: 21 December 2024
Declarations
:
: Mette Søndergaard Nielsen—Employee and shareholder of Novo Nordisk A/S. Lise Brøndsted—Employee and shareholder of Novo Nordisk A/S. Martin Kankam—One of the clinical investigators who participated in the conduct of the study, which was sponsored by Novo Nordisk; employee at Altasciences and has received clinical trial funding from Amgen, Biogen, Biohaven, Camino, DynPort, Eli Lilly, EncuraGen, NIH/DMID, Staidson and Vertex. Gaetano Morelli—Employee at Altasciences. David Nguyen—Employee at Altasciences. Trine Vang Skjøth—Employee and shareholder of Novo Nordisk A/S. Usha Rani Patted—Employee of Novo Nordisk India Private Ltd. Marloes van Hout—Employee and shareholder of Novo Nordisk A/S.
: The study protocol was approved by appropriate health authorities according to local guidelines and by the Institutional Review Board/Independent Ethics Committee Institutional Review Board, listed in the Supplementary Appendix. The study was conducted in accordance with the Declaration of Helsinki and International Council for Harmonization (ICH) Good Clinical Practice guidelines. Participants provided written informed consent prior to commencement of any study-related activities.